Načítá se...
Plasminogen Activator Inhibitor and the Risk of Cardiovascular Disease: The Framingham Heart Study
INTRODUCTION: Although plasminogen activator inhibitor (PAI-1) plays a key regulatory role in fibrinolysis, it has not been clearly shown to independently predict cardiovascular disease (CVD) among individuals without prior CVD. We investigated, in the Framingham Heart Study offspring cohort, whethe...
Uloženo v:
| Vydáno v: | Thromb Res |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5722217/ https://ncbi.nlm.nih.gov/pubmed/26896607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.thromres.2016.02.002 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|